Grid Oasis
S&P 500NASDAQ 100Dow JonesRussell 2000All StocksSectors & Industries

PCVX

+ Watchlist+ Portfolio

Vaxcyte, Inc.

Regulated industryPhysical productsSells to businessesDevelopment stageTags from an AI model reading the company description.
GridBrain

GridBrain — Sign in

GridSentinel

GridSentinel — Sign in

GridAegis

GridAegis — Sign in

Key Metrics

Previous Close
$59.40
52-Week Range
$42.40 – $90.75
Market Cap
$9.26B
P/E (TTM)
—
EPS (TTM)
-8.05
Dividend Yield
0.00%
Advanced Metrics
Price/Book
3.51
PEG Ratio
—
Return on Equity
-42.68%
Return on Assets
-24.98%
Gross Margin
0.00%
Operating Margin
0.00%
Profit Margin
0.00%
Current Ratio
4.56
Debt/Equity
0.09
Total Debt
$221.84M
Free Cash Flow
$-529.82M
Revenue Growth
—
Earnings Growth
—
Enterprise Value
$8.19B

Market Snapshot

About

Vaxcyte is a clinical-stage biotechnology company developing next-generation vaccines to prevent bacterial infectious diseases. The company focuses on pneumococcal, Group A Strep, and periodontitis prevention using its XpressCF cell-free protein synthesis platform. Lead candidate VAX-24 is a 24-valent pneumococcal conjugate vaccine.